Mistletoe therapy with Prognos – An amazing, affordable and safe cancer cure

There is no doubt today, that mistletoe therapy is very successful in treating cancer as well as many other health issues such as Lyme, fibrosis, MS etc. Each mistletoe plant growing on 13 different trees, shows a different healing profile. Mistletoe was studied for decades and was clearly demonstrated in thousands of clinical studies to have curative properties for many kind of diseases including cancer.

Prognos is an electro puncture device (EPD) developed over many decades to keep astronauts healthy in space. It works by measuring 24 points at the extremities of the 12 meridians, well known from TCM. Prognos measurement technique is recognized for its extraordinary reproducibility and accuracy. Prognos is a diagnostic and therapy device.

Prognos module Vitalomed – Visco Dendron offers a comprehensive and complete mistletoe therapy. A very sophisticated process to digitalize mistletoe plants is the key of this successful mistletoe therapy module; these frequencies can be successfully used instead of the plants.

Mistletoe therapy with Prognos helps heal cancer, prolong patients’ lifespan and significantly enhance their life quality. Mistletoe therapy shows no side effects or risks. It costs a fraction compared with chemotherapy, radiation. In Europe mistletoe therapy is officially accepted, while in USA the plants extracts were forbidden. You have a chance with Prognos Visco-Dendron module to treat your cancer patients with mistletoe. Prognos systems in North America are exclusively distributed by Lyra Nara Inc. Contact us at: 1 888 773 3196 or shop@lyranara.com

Shortness of breath is an important signal of potential disease

Shortness of breath is an often overlooked symptom of what may be heart failure or COPD (Chronic Obstructive Pulmonary Disease). New research shows that with early intervention, patients can avoid suffering and the need for hospitalisation decreases.

“The fact that people do not seek medical advice for their breathlessness is often due to people associating their symptoms with the natural process of ageing. But if you notice that you experience increased shortness of breath during exertion, you should seek medical attention,” declares Nasser Ahmadi, a researcher at the Sahlgrenska Academy and specialist in cardiology and general medicine at Capio Medical Center in Orust.

He studied breathlessness in several studies with different study designs and study populations. One study was population based and had about 1000 participants, while another one had about 100 patients who sought medical advice for their breathlessness in the primary healthcare setting.

It does not involve patients with acute shortness of breath, which can develop within a few days and should always be treated immediately. Instead, the focus is on chronic shortness of breath and adults who sought care after having shortness of breath for six weeks or more.

Like high blood pressure

“The patients who sought care for chronic breathlessness appeared to have a significantly impaired quality of life than the general population. They often had major problems completing everyday tasks. They suffered from different underlying diseases like a potential heart failure or a hidden obstructive lung disease that was developing,” says Nasser Ahmadi.

He feels that chronic shortness of breath should be considered as an equally important warning signal as high blood pressure. In order to an early detection or a correct medication of potentially chronic diseases, we need more efficient models in the primary health care to identify those who are at risk.

“My point is that the faster we identify these patients, the better prognoses we will have and the lighter the load on the healthcare system later on. Shortness of breath is often a sign of heart or lung disease because these two organs are most closely involved in the respiratory system.

According to Nasser Ahmadi most of the studies on shortness of breath that have been conducted are associated with hospitalisation, while there is significantly less research within the primary care system.

“In Sweden, few studies have been conducted in the primary care, which plays a central role in taking care of these patients,” he says.

More than being out of shape

Previous research has shown that one out of three individuals over 65 years of age in Sweden may suffer from shortness of breath during exertion. The question is how to distinguish between chronic shortness of breath and poor general fitness.

“Very often, the patient recognises that something is not right. People can compare their health with how it was previously, after all, one is his best health reference. What was I like a year ago? Was I able to do just as much or have things become considerably worse? If it is the latter, people should seek medical attention, even if you are over the age of 65 or 70,” says Nasser Ahmadi.

 

Provided by: University of Gothenburg

 

Ancient Chinese malaria remedy artemisinin fights tuberculosis

A centuries-old herbal medicine, discovered by Chinese scientists and used to effectively treat malaria, has been found to potentially aid in the treatment of tuberculosis and may slow the evolution of drug resistance.

In a promising study led by Robert Abramovitch, a Michigan State University microbiologist and TB expert, the ancient remedy artemisinin stopped the ability of TB-causing bacteria, known as Mycobacterium tuberculosis, to become dormant. This stage of the disease often makes the use of antibiotics ineffective.

The study is published in the journal Nature Chemical Biology.

“When TB bacteria are dormant, they become highly tolerant to antibiotics,” Abramovitch said, an assistant professor in the College of Veterinary Medicine. “Blocking dormancy makes the TB bacteria more sensitive to these drugs and could shorten treatment times.”

One-third of the world’s population is infected with TB and the disease killed 1.8 million people in 2015, according to the Centers for Disease Control and Prevention.

Mycobacterium tuberculosis, or Mtb, needs oxygen to thrive in the body. The immune system starves this bacterium of oxygen to control the infection. Abramovitch and his team found that artemisinin attacks a molecule called heme, which is found in the Mtb oxygen sensor. By disrupting this sensor and essentially turning it off, the artemisinin stopped the disease’s ability to sense how much oxygen it was getting.

“When the Mtb is starved of oxygen, it goes into a dormant state, which protects it from the stress of low-oxygen environments,” Abramovitch said. “If Mtb can’t sense low oxygen, then it can’t become dormant and will die.”

Abramovitch indicated that dormant TB can remain inactive for decades in the body. But if the immune system weakens at some point, it can wake back up and spread. Whether it wakes up or stays ‘asleep’ though, he said TB can take up to six months to treat and is one of the main reasons the disease is so difficult to control.

“Patients often don’t stick to the treatment regimen because of the length of time it takes to cure the disease,” he said. “Incomplete therapy plays an important role in the evolution and spread of multi-drug resistant TB strains.”

He said the research could be key to shortening the course of therapy because it can clear out the dormant, hard-to-kill bacteria. This could lead to improving patient outcomes and slowing the evolution of drug-resistant TB.

After screening 540,000 different compounds, Abramovitch also found five other possible chemical inhibitors that target the Mtb oxygen sensor in various ways and could be effective in treatment as well.

“Two billion people worldwide are infected with Mtb,” Abramovitch said. “TB is a global problem that requires new tools to slow its spread and overcome drug resistance. This new method of targeting dormant bacteria is exciting because it shows us a new way to kill it.”

 

Provided by: Michigan State University

“The Alzheimer’s Deception & The truth about a treatable disease”

Alzheimer’s disease is the pandemic of the 21st century. Rudi Assauer, a representative of a quarter million Germans who developed Alzheimer’s disease in the same year, made a clear statement. “Worldwide, there are four million new cases each year, obviously, this is an upward trend”; in 2030 half of world population will be affected by dementia. Alzheimer is 75% of all Dementia cases, both diseases have similar developments and root causes.

1907 Alois Alzheimer described in his article “About a rare disease of the cerebral cortex”, seemingly a fatal disease. The spokesman Christian Haass of the German Center for Neurodegenerative Diseases, said: “Alzheimer’s is an inevitable destiny “. This is the Alzheimer’s diseases lie: “The older a person is, the more hits him this cruel fate.”

Michael Nehls refutes this lie in his book: “The Alzheimer’s Lie and the truth about a preventable disease”. Haass analyses all factors, explaining why this disease is treatable and preventable. And he puts on a neuro-biological basis the origin of Alzheimer: The cause of Alzheimer’s disease is the decoupling of the evolutionary oldest part of the cerebral cortex, the hippocampus from the neocortex, the evolutionary youngest part of the cerebral cortex. Both parts are on perhaps the most important link within the brain, the perforant path (see Figure 1 and Figure 2.).

Image result for hippocampus perforant pathway

Fig. 1

The neocortex developed in humans more than in any other mammal.  It consists of healthy 100 million nerve cells, each having 100-100,000 synaptic connections with other neurons. Everything is connected to secure memorisation of dynamic new information processing. This happens every day, when during the sleep the information saved in hippocampus are transferred to the neocortex. Thus, hippocampus is the real reservoir of memory and therefore here are produced every day new neuronal cells to absorb daily new information accessing our brain. This is known as synaptogenesis made possible by the new stem cells located in hippocampus.

Related image

 Figure 2

With my first great teacher, the founder of Neurobiology, Hans Jürgen Mathies, we counted in the rats the synapses before and after learning and easily found, that there is an enormous number of new neuronal connections every day. We could not believe our eyes, because that could not go the whole life like this, without having this immense volume of information being transferred and stored somewhere else. The localisation of the memory contents remained for us at that time still a great mystery. The extremely fast development of nerve cells (neurogenesis) in the hippocampus is nowadays firmly confirmed. It is also clearly confirmed that the information is transferred to be stored in neocortex, every night during the sleep.

In the neocortex, there are 100 billion neuronal cells with 100-1000 000 per neuron connections, almost an infinite store-house. So, the neocortex is the place of our long-term memory in which the information of the whole life is stored. What remains in hippocampus is the short memory, only a brief information as an Internet address for retrieving the used information. This enables us to wake up every morning to reopen hippocampus capacity to store and collect new information.
In Alzheimer’s, the perforant path is impaired or destroyed. The information cannot get from the hippocampus to the neocortex, nor can the information be retrieved. The connection is disrupted in both directions. The cerebral cortex does not get new “orders” from the hippocampus. So, the neurons die according to the principle “use it or lose is”. This theory is accurately presented in the book of Michael Nehls. 

Is Alzheimer curable? More than 8 months I experienced a 75 years old Colombian women named Graciela together with her daughter. It is a case in which after the Neuron regenerative Alzheimer Therapy (NAT) was applied, was achieved a complete regression of Alzheimer within 8 months.

  1. Situation and symptoms prior to treatment:
    Graciela first arrived on 08.12.2014; at that time, she did not know in what place she was, she did not know how old she was. She was not sure what she had eaten for breakfast. She did not know that they had arrived a day before. She did not know in which hotel she slept. None of emotionally important events she could remember. Her daughter said she got a year ago, the diagnosis “Alzheimer”. However, they had long ago noticed by extreme forgetfulness that she could not live alone. 

2. The following treatment was then performed on two consecutive days:

The Neuroregenerative Alzheimer Therapy (NAT) is using auricular micro-implants for continuous stimulation of the hippocampus, the entire limbic system and the cerebral cortex, especially parietal and temporal lobes. These are the first cerebral cortex zones being affected by Alzheimer’s disease. 

3. The second day were given further instructions to the family of the patient:

  • Provide daily small mental tasks, first on lowest level and assess accuracy of the answers. Initially small addition problems, subtraction, a little short-term memory to be retrieved first, only for the day, and later also by experiences of the previous day. It was important that the tasks were never severe, to feel the success
  • As therapy support was considered also the common joy of the patient loving family.  With the slow recovery rose the sense of achievement enthusiasm
  • The patient must have a “life purpose”, a hobby
  • Diet was to avoid carbohydrates, eat lots of fish, olive oil (served cold), coconut oil also for frying, chilli and turmeric recommended
  • Daily exercise, such as walking in the sun light
  • A recommended dietary supplement was NADH “RAPID ENERGY” by Prof. Birkmayer, Vienna, to improve the oxygenation of the brain also.
  • Drink sufficient water per day in combination with 2 capsules Hyaktiv- capsules / day (ingredient: hyaluronic acid) to improve the water supply in the cells
  • Coffee but not more than 5 cups throughout the day
  • To support a healthy body, a balanced ANS and brain hemispheres we used Kindling Easy, (https://lyranara.com/product/kindling-easy/), Geno62 (https://lyranara.com/product/geno62/), Aquatone04 (https://lyranara.com/product/aquatone/) and neurofeedback stimulation

 8 months later:

  • On the question of whether and how they had come, she said, “The last 1 hour by plane.”
  • She said: “we stay in a hotel which name she knew”.
  • All questions regarding yesterday she could report in detail.
  • She knew what she eats for breakfast on that day.
  • On the question, how old she was now, she said, after she glanced at the ceiling “76”. It was right, she knew they had a birthday party.
  • The daughter and the family were overjoyed and showed this extensively.
  • Finally, she was asked about her work and she answered, as confirmed in detail by the family: she deals extensively with handwork.
  • She is walking alone, no need for her family to move her.

Conclusions

The stimulation of the corresponding “points” per ABS method, using “Permanent Titanium-implants” (developed by Dr. U. Werth) led to a total regression of Alzheimer’s disease. Furthermore, of advantage was to combine the ABS therapy along with Michael Nehls’s preventive measures described above.

With the time, we treated more Alzheimer cases and we can say that the outlook for this deadly disease is very positive. It is possible to quantify the effect of NAT therapy by measuring the volume of hippocampus, which in case of Alzheimer is permanently shrinking; this can be done by using bolometry, a classical method for volume measurement. In renowned universities and clinics in Europe are ongoing double blind studies, to be finished by 2018; then we will be able to confirm a very promising therapy for Dementia and Alzheimer.

Pharma industry and medical establishment likes to promote the idea that Alzheimer and Dementia are not treatable. They are following a “vaccination” pathway; we already know and can confirm today, that this is the deadly treatment. Any kind of vaccines or pharmaceutical drugs never reacted positive in this kind of diseases.

Contact us for treatments arrangements. Treatments are now possible only in Europe and we hope to bring this soon to North America. We are in the phase of crowdfunding this project.

Provided by Dr. Med. U. Wehrt and Dr. Christine Siepe